Review of modern trends in the treatment of chronic bacterial prostatitis (C.B.P.).
Careful, lower urinary tract localization studies have to be used to classify patients in the chronic bacterial prostatitis group and others. Considerable progress has been made in understanding the pathophysiology and developing rational approaches for treatment of patients with chronic bacterial prostatitis. Ciprofloxacin is a new quinolone carboxylic acid derivate with marked activity against both gram-negative and gram-positive bacteria. A critical analysis of the most recent achievements in the area of chronic bacterial prostatitis is presented.